ASCO Annual Meeting: Genitourinary

Results of the ENZAMET trial presented at 2022 ASCO continue to support use of enzalutamide in patients with metastatic hormone-sensitive prostate cancer.

Similar overall survival, better patient-reported outcomes, and fewer adverse effects were observed when patients were treated with 177Lu-PSMA-617 vs cabazitaxel in metastatic castration-resistant prostate cancer.

Lenvatinib plus pembrolizumab decreased the risk of disease progression or death on second-line therapy by 50% compared with sunitinib in the phase 3 CLEAR trial.

A manageable safety profile and good clinical activity were observed with toripalimab in Chinese patients with urothelial carcinoma.

An exploratory analysis of the JAVELIN Bladder 100 study indicated long-term overall survival benefit for patients with advanced urothelial carcinoma who received avelumab maintenace, without regard for treatment given in the second-line setting.

Results of the phase 3 EVEREST trial show adjuvant everolimus improved recurrence-free survival for patients with very high-risk renal cell carcinoma.

Results from the phase 2 ATLANTIS trial did not show a benefit of cabozantinib in patients with advanced urothelial carcinoma compared with the placebo, but the treatment appeared to be tolerable.

Results of the COSMIC-021 trial presented at ASCO 2022 show promise of cabozantinib plus atezolizumab for urothelial carcinoma.

Judd Moul, MD, discusses the gravity of new data on systemic therapies for men with castration-resistant prostate cancer and how they can be of use during the COVID-19 pandemic.

Robert A. Figlin, MD, discusses the potential role of adjuvant immunotherapy for patients with bladder cancer.

CancerNetwork® sat down with Edmund Qiao at the 2021 American Society of Clinical Oncology Annual Meeting to talk about prostate-specific antigen screening and prostate cancer prevention in African American men.

Robert A. Figlin, MD, details how his institution, Cedars-Sinai Cancer, is aiming to fully understand the cancer journey for those with genitourinary malignancies.

Robert A. Figlin, MD, highlights toxicities that patients with renal cell carcinoma experience while on cabozantinib.

During a discussion at 2021 ASCO, Neal D. Shore, MD, said he was most excited to see data from the phase 3 VISION trial of lutetium-177-PSMA-617 in metastatic castration-resistant prostate cancer.

At ASCO 2021, Chung-Han Lee, MD, PhD, discussed an ongoing trial looking at pembrolizumab plus lenvatinib as frontline therapy for non–clear cell renal cell carcinoma.

CancerNetwork® sat down with Robert A. Figlin, MD, at the 2021 ASCO Annual Meeting to discuss the results of the KEYNOTE-564 trial with adjuvant pembrolizumab in patients with resected clear cell renal cell carcinoma.

Neal D. Shore, MD, FACS, discusses the importance of multidisciplinary care for patients with advanced prostate cancer.

Petros Grivas, MD, PhD, regarding updates in genitourinary oncology that were read out at the meeting.

Petros Grivas, MD, PhD, discusses the impact of avelumab on patients with advanced urothelial carcinoma in the first-line maintenance setting.

Motzer discussed time to deterioration end points for patients with advanced renal cell carcinoma treated with pembrolizumab and lenvatinib in the first-line setting.

Almost all patients with nonmetastatic castration-resistant prostate cancer treated on the phase 3 ARAMIS trial were able to receive the full planned dose of darolutamide for their disease.

CancerNetwork® sat down with Robert A. Figlin, MD, at the 2021 ASCO Annual Meeting to discuss results of the CANTATA trial of cabozantinib with or without telaglenastat.

Choueiri detailed combination treatments with follow-up data presented at the 2021 ASCO Annual Meeting.

The recommended phase 2 dose of pembrolizumab plus cabozantinib induced a response with a manageable safety profile for patients with mRCC.

Lenvatinib plus pembrolizumab was efficacious for patients with advanced renal cell carcinoma and performed well in subgroup analyses of International Metastatic Renal Cell Carcinoma Database Consortium risk categories and target kidney lesions.

Adding abiraterone acetate and prednisone to androgen-deprivation therapy and docetaxel improved radiographic progression-free survival for men with de novo metastatic castration-sensitive prostate cancer.

A post hoc analysis of the CLEAR trial shows that patients may derive an overall survival benefit with lenvatinib plus everolimus versus sunitinib for frontline treatment of RCC, with efficacy ongoing.

Despite failure to reach the primary end point of statistically significant overall survival benefit, TAK-700 plus androgen-deprivation therapy for metastatic hormone-sensitive prostate cancer may be a valid treatment option for some patients.

CancerNetwork® sat down with Matthew D. Galsky, MD, at the 2021 ASCO Annual Meeting to discuss his thoughts on research he believes has the greatest potential to impact standard of care treatment of bladder cancer.

Disparities regarding comprehensive genomic profiling came to light during a presentation at the 2021 ASCO Annual Meeting.